Amanote Research
Register
Sign In
Pcn69 - Budget Impact of Substituting Biosimilar Trastuzumab (Ct-P6) in Treating Gastric Cancer and Breast Cancer in 28 European Countries
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.151
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
D. Suh
S. Lee
D. Suh
Publisher
Elsevier BV
Related search
Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries
European Journal of Health Economics
Health Policy
Economics
Econometrics
Finance
Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Gastric Cancer and Trastuzumab: First Biologic Therapy in Gastric Cancer
Therapeutic Advances in Medical Oncology
Oncology
Efficacy and Safety of CT-P6 Versus Reference Trastuzumab in HER2-positive Early Breast Cancer: Updated Results of a Randomised Phase 3 Trial
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
PMD13 Assessing the Budget Impact of Using ScanBag® in CT in Six European Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Crohn's Disease in Six Central Eastern European Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A Phase I Dose-Escalation Study of a Biosimilar Trastuzumab in Chinese Metastasis Breast Cancer Patients
SpringerPlus
Multidisciplinary
Household Budget Survey Nutritional Data in Relation to Mortality From Coronary Heart Disease, Colorectal Cancer and Female Breast Cancer in European Countries
European Journal of Clinical Nutrition
Medicine
Nutrition
Dietetics
Trastuzumab-Resistance and Breast Cancer
